Our extensive network includes 68 plasma collection centers operated by KEDPLASMA in the United States, 8 centers managed by UNICAplasma in the Czech Republic, and 7 production facilities across 5 countries. With a global community of 5,200 people, this infrastructure enables us to distribute 38 life-enhancing and life-saving products in over 100 countries, positioning us as the fifth largest player in the plasma-derived sector worldwide.

With our dedication to developing solutions that address unmet medical needs in rare and ultra-rare diseases, we envision a world where the union of science and care knows no bounds.

In partnership with the medical and scientific community, institutions, patient advocacy groups, and research organizations, we drive sustainable innovation and improve patient care.

What sets us apart from other biopharma companies is our commitment to every detail, every person, every interaction. Whether engaging with donors, supporting patients, empowering our employees, every connection we make impacts someone, somewhere. We call these “rare connections”.

The Power of Rare Connections

No matter how you do it, when you save a life, the world is changed forever. Creating a chain of hope and compassion that transcends an individual action, this sense of human nature drives one person to give the gift of life to many.

At Kedrion, we believe the beauty and responsibility of what we do lies in these connections. That’s why we foster meaningful relationships that others often overlook.

Our strategy prioritizes every detail, every person, every interaction. And this dedication not only changes patients’ lives, but drives our business forward; crafting plasma-derived therapies, treating rare diseases, and developing innovative solutions to treat the humans of tomorrow, we’re committed to digging deeper so we can go where no one else has gone.

Embracing the details of every connection. We create a world where the union of science and care knows no bounds. From donors to patients, doctors to specialized pharmacists, even molecules to cells, we believe in the power of rare connections to impact millions of lives.

Led by UK-based specialists in plasma therapies and supported by an experienced team, we apply our scientific expertise and resources to improve existing production and the development of new products, using the latest developments in medical science and clinical practice.

Operations play a fundamental role in the Elstree manufacturing facility, ensuring the efficient and high-quality production of essential plasma-derived therapies. This site is a critical hub for the production of life-saving treatments, including albumin-based therapies, immunoglobulins, and Factor X concentrates.

The seamless coordination of operations at Elstree is vital for maintaining the stringent quality and safety standards required for plasma-derived products. Given the complex nature of these biopharmaceuticals, every aspect of manufacturing—from plasma collection and fractionation to purification and final formulation—must be meticulously managed.

The R&D capability supports the strategy for new product development, prioritizing the movement of new products along the development lifecycle, and into the commercial market.

An example of this dedication is the development of the first and only approved treatment specifically indicated for a rare hereditary deficiency. The product is a unique, targeted therapy for a rare bleeding disorder.
This hereditary deficiency was an overlooked and unmet need, affecting about one in a million people in the general population. The deficiency can result in many different types of bleeds, including severe gastrointestinal or life-threatening intracranial bleeds.
To develop this product, BPL worked closely in the US with patient advocacy groups and experts to identify and reach patients. The product, which is the first and only approved treatment specifically for this condition, has rapidly become successful globally and that has improved, and continues to improve, the lives of people born with this rare bleeding disorder.